Jonathan B. Gill, MD

Professor
University of Texas MD Anderson Cancer Center
Houston, Texas, United States

Disclosure information not submitted.

Presentation(s):

• Paper 22 - A MULTI-CENTER PHASE II STUDY OF THE ANTI-GD2 HUMANIZED MONOCLONAL ANTIBODY NAXITAMAB IN COMBINATION WITH GM-CSF IN RECURRENT OSTEOSARCOMA.

  Thursday, November 14, 2024
  1:45 PM – 3:15 PM PST

• Paper 23 - A PHASE 1/2 TRIAL OF GEMCITABINE, DOCETAXEL, AND HYDROXYCHLOROQUINE IN ADVANCED METASTATIC OSTEOSARCOMA: FINAL RESULTS

  Thursday, November 14, 2024
  1:45 PM – 3:15 PM PST